AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17388091 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise 2 times per week
Number of subjects: 50
Study 17388091 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise 3 times per week
Number of subjects: 50
Study 17388091 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 50
Study 16623031 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction (CAI) on Ascaris lumbricoides
Number of subjects: 60
Study 16623031 — intervention group
Group type: COMPARATOR
Intervention: Hard copy lessons on Ascaris lumbricoides
Number of subjects: 60
Study 16623031 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction (CAI) on Enterobius vermicularis
Number of subjects: 60
Study 16623031 — intervention group
Group type: COMPARATOR
Intervention: Hard copy lessons on Enterobius vermicularis
Number of subjects: 60
Study 16623031 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction (CAI)
Number of subjects: 60
Study 16623031 — intervention group
Group type: COMPARATOR
Intervention: Hard copy lessons
Number of subjects: 60
Study 12037148 — intervention group
Group type: EXPERIMENTAL
Intervention: hOKT3gamma1(Ala‐Ala) monoclonal antibody treatment for 14 days
Number of subjects: 24
Study 12037148 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibody treatment)
Number of subjects: 24
Study 12037148 — intervention group
Group type: EXPERIMENTAL
Intervention: hOKT3gamma1(Ala‐Ala) monoclonal antibody treatment
Number of subjects: 24
Study 10216324 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzyl alcohol 9% with 1:100,000 epinephrine
Number of subjects: 30
Study 10216324 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% with 1:100,000 epinephrine
Number of subjects: 30
Study 10216324 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiologic saline solution)
Number of subjects: 30
Study 8251017 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-pressure resistance skills program
Number of subjects: 168
Study 8251017 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 168
Study 3505528 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheezers Anonymous (WA) program
Number of subjects: 79
Study 3505528 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 79
Study 29861803 — intervention group
Group type: EXPERIMENTAL
Intervention: PECS II block
Number of subjects: 80
Study 29861803 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 26857829 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent sun protection program (read-along book, swim shirt, weekly text-message reminders)
Number of subjects: 300
Study 26857829 — intervention group
Group type: COMPARATOR
Intervention: Control group (information usually provided at a well-child visit)
Number of subjects: 300
Study 24534682 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-media tablet device delivering graphic and verbal information
Number of subjects: 0
Study 24534682 — intervention group
Group type: COMPARATOR
Intervention: Audio device delivering verbal information only
Number of subjects: 0
Study 22466971 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular hypothermia
Number of subjects: 26
Study 20578922 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SALC)
Number of subjects: 60
Study 20578922 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GALC)
Number of subjects: 60
Study 18051666 — intervention group
Group type: EXPERIMENTAL
Intervention: Jail reentry programs tailored to gender, age, and ethnic/racial differences
Number of subjects: 1946
Study 16083521 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone prolonged release 150-450 mg/day (n = 55)
Number of subjects: 108
Study 16083521 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine 20-40 mg/day (n = 53)
Number of subjects: 108
Study 12404164 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated treatment with praziquantel
Number of subjects: 0
Study 12404164 — intervention group
Group type: COMPARATOR
Intervention: Control group (children who did not receive chemotherapy)
Number of subjects: 0
Study 10594405 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA
Number of subjects: 18
Study 10594405 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Arginine (L-Arg)
Number of subjects: 18
Study 10594405 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA + L-Arg
Number of subjects: 18
Study 10594405 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 18
Study 8677930 — intervention group
Group type: EXPERIMENTAL
Intervention: 125-mg 13C urea breath test at 30 min
Number of subjects: 120
Study 8677930 — intervention group
Group type: EXPERIMENTAL
Intervention: 250-mg 13C urea breath test at 40 min
Number of subjects: 120
Study 8677930 — intervention group
Group type: EXPERIMENTAL
Intervention: 125-mg 13C urea breath test
Number of subjects: 120
Study 1961376 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (Germed) 50 or 75 mg daily depending on body weight, treatment stopped after two months for one month
Number of subjects: 21
Study 1961376 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (Encorton, Polfa) 5 or 10 mg daily
Number of subjects: 21
Study 30704795 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Number of subjects: 3953
Study 30704795 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 3953
Study 26971745 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shockwave therapy (rESWT) - 0.340 mJ/mm2, 2000 shots
Number of subjects: 12
Study 26971745 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shockwave therapy (rESWT)
Number of subjects: 12
Study 25895021 — intervention group
Group type: EXPERIMENTAL
Intervention: IPX066 (carbidopa-levodopa)
Number of subjects: 617
Study 22913655 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Form of the Mini-Mental State Examination (SMMSE)
Number of subjects: 606
Study 22090070 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory flow increase technique (EFIT) performed 2 hours after feeding
Number of subjects: 18
Study 22090070 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory flow increase technique (EFIT) performed 3 hours after feeding
Number of subjects: 18
Study 19089890 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg twice per day + Vaginal conjugated equine estrogen 0.625 mg twice a week
Number of subjects: 80
Study 19089890 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine 2 mg twice per day
Number of subjects: 80
Study 16860807 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 80
Study 16860807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 14969666 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing with tampons
Number of subjects: 14
Study 14969666 — intervention group
Group type: COMPARATOR
Intervention: NuvaRing alone
Number of subjects: 14
Study 11430419 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose lenograstim (263 microg/day)
Number of subjects: 44
Study 11430419 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose lenograstim (131.5 microg/day)
Number of subjects: 44
Study 9551010 — intervention group
Group type: EXPERIMENTAL
Intervention: Family planning intervention with husband's participation
Number of subjects: 1800
Study 9551010 — intervention group
Group type: COMPARATOR
Intervention: Usual family planning care
Number of subjects: 1800
Study 9551010 — intervention group
Group type: COMPARATOR
Intervention: Family planning intervention targeting wife only
Number of subjects: 1800
Study 9315987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 671
Study 9315987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 671
Study 2635871 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg suppositories twice daily)
Number of subjects: 112
Study 2635871 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo suppositories)
Number of subjects: 112
Study 415870 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-methylpyrazole (4-MP, 7 mg/kg body wt i.v.)
Number of subjects: 0
Study 415870 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (0.6 g/kg body wt)
Number of subjects: 0
Study 31237045 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground gait training with rhythmic auditory stimulation (RAS, n=6)
Number of subjects: 12
Study 31237045 — intervention group
Group type: COMPARATOR
Intervention: Overground gait training without rhythmic auditory stimulation (GT, n=6)
Number of subjects: 12
Study 30552951 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 76
Study 30552951 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 76
Study 27431576 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 plus closed suction drainage
Number of subjects: 80
Study 27431576 — intervention group
Group type: COMPARATOR
Intervention: Drainage-only
Number of subjects: 80
Study 26164096 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment including doxorubicin (vincristine 1.5 mg/m² + actinomycin D 45 μg/kg + doxorubicin 50 mg/m² every 6 weeks)
Number of subjects: 583
Study 26164096 — intervention group
Group type: COMPARATOR
Intervention: Treatment excluding doxorubicin (vincristine 1.5 mg/m² + actinomycin D 45 μg/kg)
Number of subjects: 583
Study 24166522 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF 1‐6 cycles
Number of subjects: 167
Study 24166522 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF 1‐2 cycles
Number of subjects: 167
Study 24166522 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF 1‐6 cycles vs G‐CSF 1‐2 cycles
Number of subjects: 167
Study 21305315 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary vitrectomy (PV)
Number of subjects: 0
Study 21305315 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral buckling (SB)
Number of subjects: 0
Study 19476724 — intervention group
Group type: EXPERIMENTAL
Intervention: GlucoWatch Biographer
Number of subjects: 404
Study 19476724 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniMed Continuous Glucose Monitoring System (CGMS)
Number of subjects: 404
Study 19476724 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (standard treatment with nurse feedback)
Number of subjects: 404
Study 19476724 — intervention group
Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 404
Study 17708161 — intervention group
Group type: EXPERIMENTAL
Intervention: HyperHaes solution (250ml 7.2% NaCl/6% HES solution)
Number of subjects: 80
Study 17708161 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate (500 ml Ringer's acetate solution)
Number of subjects: 80
Study 14767730 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg
Number of subjects: 10
Study 14767730 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 10
Study 11521723 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus trastuzumab (Herceptin)
Number of subjects: 469
Study 11521723 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 469
Study 9475695 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrethrin-piperonyl-butoxide pediculicide (RID; Py-PB)
Number of subjects: 190
Study 9475695 — intervention group
Group type: COMPARATOR
Intervention: Permethrin pediculicide (NIX; PM)
Number of subjects: 190
Study 7846590 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct current stimulation
Number of subjects: 0
Study 7846590 — intervention group
Group type: COMPARATOR
Intervention: No direct current stimulation (Control)
Number of subjects: 0
Study 3285731 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine po approximately 5 micrograms.kg‐1
Number of subjects: 80
Study 3285731 — intervention group
Group type: COMPARATOR
Intervention: Diazepam po (0.1 mg.kg‐1)
Number of subjects: 80
Study 29294791 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowering Youth Through Interpersonal Violence Prevention Program (EYIPP)
Number of subjects: 24
Study 29294791 — intervention group
Group type: EXPERIMENTAL
Intervention: EYIPP
Number of subjects: 24
Study 29294791 — intervention group
Group type: COMPARATOR
Intervention: Control group (those who refused to participate in services)
Number of subjects: 24
Study 29294791 — intervention group
Group type: COMPARATOR
Intervention: Control group (eligible youths who declined services)
Number of subjects: 24
Study 30942015 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm moxibustion combined with conventional quadriceps strength training
Number of subjects: 174
Study 30942015 — intervention group
Group type: COMPARATOR
Intervention: Conventional quadriceps strength training
Number of subjects: 174
Study 28551531 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 50
Study 28551531 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological methods (Control group)
Number of subjects: 50
Study 25111236 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of an angiotensin I-converting enzyme inhibitor and angiotensin II-receptor blocker
Number of subjects: 558
Study 25111236 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin I-converting enzyme inhibitor alone
Number of subjects: 558
Study 25111236 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blood pressure (<110/75 mm Hg)
Number of subjects: 558
Study 25111236 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure (120-130/70-80 mm Hg)
Number of subjects: 558
Study 24112359 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn chlorhexidine cleansing
Number of subjects: 18985
Study 24112359 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 18985
Study 24112359 — intervention group
Group type: EXPERIMENTAL
Intervention: No exclusive breastfeeding
Number of subjects: 18985
Study 21954530 — intervention group
Group type: EXPERIMENTAL
Intervention: T-piece (4 L/min)
Number of subjects: 40
Study 21954530 — intervention group
Group type: COMPARATOR
Intervention: CPAP (PEEP <= 5 cm H2O, FiO2 <= 0.4)
Number of subjects: 40
Study 19700946 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychosocial therapy (BPST) for 4 weeks
Number of subjects: 318
Study 16917884 — intervention group
Group type: EXPERIMENTAL
Intervention: Kid's Block Food Frequency Questionnaire (Kid's Block FFQ)
Number of subjects: 61
Study 16917884 — intervention group
Group type: COMPARATOR
Intervention: 24-hour recall
Number of subjects: 61
Study 15324466 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (2.5 mg/kg) alone
Number of subjects: 66
Study 15324466 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (2.5 mg/kg) plus Ivermectin (200 microg/kg)
Number of subjects: 66
Study 15324466 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (2.5 mg/kg) plus Albendazole (400 mg)
Number of subjects: 66
Study 15324466 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin (200 microg/kg) alone
Number of subjects: 66
Study 15324466 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (400 mg) alone
Number of subjects: 66
Study 11153551 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (2 microg/kg) 5 min before MH placement
Number of subjects: 45
Study 11153551 — intervention group
Group type: EXPERIMENTAL
Intervention: Local lidocaine infiltration (3 ml 1% plain lidocaine) at each pin site 1 min before MH placement
Number of subjects: 45
Study 11153551 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl + local lidocaine infiltration
Number of subjects: 45
Study 9342546 — intervention group
Group type: EXPERIMENTAL
Intervention: 37/40 kD antibodies in Type 1a diabetic patients
Number of subjects: 225
Study 9342546 — intervention group
Group type: EXPERIMENTAL
Intervention: 37/40 kD antibodies in Type 1b diabetic patients
Number of subjects: 225
Study 9342546 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD antibodies and/or 37/40 kD antibodies
Number of subjects: 225
Study 9342546 — intervention group
Group type: COMPARATOR
Intervention: GAD antibodies in schoolchildren
Number of subjects: 225
Study 9342546 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ICA with at least two other markers in relatives
Number of subjects: 225
Study 9342546 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of diabetes in ICA-positive non-diabetic subjects
Number of subjects: 225
Study 9342546 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of multiple antibodies in ICA-positive non-diabetic subjects
Number of subjects: 225
Study 9342546 — intervention group
Group type: COMPARATOR
Intervention: Association of ICA with at least two other markers in non-progressing subjects
Number of subjects: 225
Study 1547194 — intervention group
Group type: EXPERIMENTAL
Intervention: niacin/colestipol plus diet therapy
Number of subjects: 350
Study 1547194 — intervention group
Group type: EXPERIMENTAL
Intervention: computer-based quantitative coronary angiography (QCA)
Number of subjects: 350
Study 1547194 — intervention group
Group type: EXPERIMENTAL
Intervention: panel-based estimates
Number of subjects: 350
Study 1547194 — intervention group
Group type: EXPERIMENTAL
Intervention: QCA
Number of subjects: 350
Study 3939740 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 21
Study 3939740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 30712391 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmirtazapine (2.25, 4.5, 9.0, or 18.0 mg)
Number of subjects: 1888
Study 30712391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1888
Study 30112861 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic outdoor urban pollution (Baoding)
Number of subjects: 204
Study 30112861 — intervention group
Group type: COMPARATOR
Intervention: Moderate outdoor urban pollution (Dalian)
Number of subjects: 204
Study 26481674 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback (rtfMRI NF)
Number of subjects: 16
Study 26481674 — intervention group
Group type: COMPARATOR
Intervention: Sham feedback (Control group)
Number of subjects: 16
Study 25339753 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tsDCS
Number of subjects: 0
Study 25339753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tsDCS
Number of subjects: 0
Study 25339753 — intervention group
Group type: COMPARATOR
Intervention: Sham tsDCS
Number of subjects: 0
Study 22607563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent granulocyte and monocyte apheresis (GMA)
Number of subjects: 21
Study 22607563 — intervention group
Group type: COMPARATOR
Intervention: Oral mercaptopurine (0.5 mg/kg per day)
Number of subjects: 21
Study 21135366 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD (n=311)
Number of subjects: 653
Study 21135366 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD with appropriate therapy
Number of subjects: 653
Study 21135366 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD with no appropriate therapy
Number of subjects: 653
Study 21135366 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD shock therapy
Number of subjects: 653
Study 21135366 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (Control, n=342)
Number of subjects: 653
Study 17624213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng supplementation (3 grams of 100% ginseng orally daily for 8 weeks)
Number of subjects: 60
Study 17624213 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose powder, same dosage and duration as ginseng)
Number of subjects: 60
Study 17624213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng supplementation
Number of subjects: 60
Study 17624213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15903359 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (6 g of creatine monohydrate per day)
Number of subjects: 40
Study 15903359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12167507 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 154
Study 12167507 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 154
Study 12167507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 9523367 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol inhalation
Number of subjects: 14
Study 9523367 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 14
Study 9638196 — intervention group
Group type: EXPERIMENTAL
Intervention: Late potentials (LP) group (25 patients)
Number of subjects: 125
Study 9638196 — intervention group
Group type: COMPARATOR
Intervention: No late potentials (LP) group (100 patients)
Number of subjects: 125
Study 2782125 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving as a strong desire
Number of subjects: 0
Study 2782125 — intervention group
Group type: COMPARATOR
Intervention: Craving as any desire or urge
Number of subjects: 0
Study 336651 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 0
Study 336651 — intervention group
Group type: COMPARATOR
Intervention: Benztropine
Number of subjects: 0
Study 31641729 — intervention group
Group type: EXPERIMENTAL
Intervention: Low RBC DHA-EPA concentration (≤4.82%)
Number of subjects: 1680
Study 31641729 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in RBC DHA-EPA from baseline
Number of subjects: 1680
Study 29039802 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 22)
Number of subjects: 45
Study 29039802 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 23)
Number of subjects: 45
Study 26042474 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 37
Study 23676577 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg once daily
Number of subjects: 360
Study 23676577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 20512069 — intervention group
Group type: COMPARATOR
Intervention: Male experimenter
Number of subjects: 100
Study 20512069 — intervention group
Group type: COMPARATOR
Intervention: Female experimenter
Number of subjects: 100